Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Autoimmune Disorders

  Free Subscription


Articles published in Acta Neurol Scand

Retrieve available abstracts of 79 articles:
HTML format
Text format



Single Articles


    May 2018
  1. SEBASTIAO E, Motl RW
    Body mass index and cardiorespiratory fitness in persons with multiple sclerosis.
    Acta Neurol Scand. 2018 May 11. doi: 10.1111/ane.12959.
    PubMed     Text format     Abstract available


  2. ABDOLLAHPOUR I, Nedjat S, Mansournia MA, Eckert S, et al
    Infectious exposure, antibiotic use, and multiple sclerosis: A population-based incident case-control study.
    Acta Neurol Scand. 2018 May 9. doi: 10.1111/ane.12958.
    PubMed     Text format     Abstract available


  3. HONG Y, Li HF, Romi F, Skeie GO, et al
    HLA and MuSK-positive myasthenia gravis: A systemic review and meta-analysis.
    Acta Neurol Scand. 2018 May 7. doi: 10.1111/ane.12951.
    PubMed     Text format     Abstract available


    April 2018
  4. AXELSSON M, Sjogren M, Andersen O, Blennow K, et al
    Neurofilament light protein levels in cerebrospinal fluid predict long-term disability of Guillain-Barre syndrome: A pilot study.
    Acta Neurol Scand. 2018 Apr 6. doi: 10.1111/ane.12927.
    PubMed     Text format     Abstract available


    March 2018
  5. HEYDARPOUR P, Manouchehrinia A, Beiki O, Mousavi SE, et al
    Smoking and worsening disability in multiple sclerosis: A meta-analysis.
    Acta Neurol Scand. 2018 Mar 15. doi: 10.1111/ane.12916.
    PubMed     Text format     Abstract available


  6. VISTBAKKA J, Sumelahti ML, Lehtimaki T, Elovaara I, et al
    Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR-376c-3 in multiple sclerosis patients.
    Acta Neurol Scand. 2018 Mar 12. doi: 10.1111/ane.12921.
    PubMed     Text format     Abstract available


  7. RAHMANZADEH R, Weber MS, Bruck W, Navardi S, et al
    B cells in multiple sclerosis therapy-A comprehensive review.
    Acta Neurol Scand. 2018 Mar 7. doi: 10.1111/ane.12915.
    PubMed     Text format     Abstract available


    February 2018
  8. MANI A, Chohedri E, Ravanfar P, Mowla A, et al
    Efficacy of group cognitive rehabilitation therapy in multiple sclerosis.
    Acta Neurol Scand. 2018 Feb 7. doi: 10.1111/ane.12904.
    PubMed     Text format     Abstract available


    January 2018
  9. CHANDAN S, Shukla G, Gupta A, Srivastava A, et al
    Acute-onset Restless legs syndrome in acute neurological conditions-a prospective study on patients with the Guillain-Barre syndrome and acute stroke.
    Acta Neurol Scand. 2018 Jan 22. doi: 10.1111/ane.12890.
    PubMed     Text format     Abstract available


  10. MESCHERIAKOVA JY, Hintzen RQ
    No excess of autoimmune diseases in multiple sclerosis families from the Netherlands.
    Acta Neurol Scand. 2018 Jan 7. doi: 10.1111/ane.12896.
    PubMed     Text format     Abstract available


    December 2017
  11. OLSSON A, Oturai AB, Sondergaard HB, Sellebjerg F, et al
    Bone microarchitecture and bone mineral density in multiple sclerosis.
    Acta Neurol Scand. 2017 Dec 21. doi: 10.1111/ane.12884.
    PubMed     Text format     Abstract available


  12. ZECCA C, Antozzi CG, Torri Clerici V, Ferrazzini M, et al
    Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation.
    Acta Neurol Scand. 2017 Dec 3. doi: 10.1111/ane.12882.
    PubMed     Text format     Abstract available


  13. HEESEN C, Haase R, Melzig S, Poettgen J, et al
    Perceptions on the value of bodily functions in multiple sclerosis.
    Acta Neurol Scand. 2017 Dec 3. doi: 10.1111/ane.12881.
    PubMed     Text format     Abstract available


    November 2017
  14. IBRAHIM J, Grapperon AM, Manfredonia F, van den Bergh PY, et al
    Serial electrophysiology in Guillain-Barre syndrome: A retrospective cohort and case-by-case multicentre analysis.
    Acta Neurol Scand. 2017 Nov 21. doi: 10.1111/ane.12872.
    PubMed     Text format     Abstract available


  15. ZETTERBERG H
    Fluid biomarkers for microglial activation and axonal injury in multiple sclerosis.
    Acta Neurol Scand. 2017;136 Suppl 201:15-17.
    PubMed     Text format     Abstract available


  16. LYCKE J
    Trials of antivirals in the treatment of multiple sclerosis.
    Acta Neurol Scand. 2017;136 Suppl 201:45-48.
    PubMed     Text format     Abstract available


  17. CELIUS EG
    Infections in patients with multiple sclerosis: Implications for disease-modifying therapy.
    Acta Neurol Scand. 2017;136 Suppl 201:34-36.
    PubMed     Text format     Abstract available


  18. WEKERLE H
    Nature, nurture, and microbes: The development of multiple sclerosis.
    Acta Neurol Scand. 2017;136 Suppl 201:22-25.
    PubMed     Text format     Abstract available


  19. FREDERIKSEN JL, Topsoe Mailand M
    Vaccines and multiple sclerosis.
    Acta Neurol Scand. 2017;136 Suppl 201:49-51.
    PubMed     Text format     Abstract available


  20. WENDEL-HAGA M, Celius EG
    Is the hygiene hypothesis relevant for the risk of multiple sclerosis?
    Acta Neurol Scand. 2017;136 Suppl 201:26-30.
    PubMed     Text format     Abstract available


    August 2017
  21. WALLIN MT, Culpepper WJ, Maloni H, Kurtzke JF, et al
    The Gulf War era multiple sclerosis cohort: 3. Early clinical features.
    Acta Neurol Scand. 2017 Aug 22. doi: 10.1111/ane.12810.
    PubMed     Text format     Abstract available


    July 2017
  22. ANDERSEN O, Hildeman A, Longfils M, Tedeholm H, et al
    Diffusion tensor imaging in multiple sclerosis at different final outcomes.
    Acta Neurol Scand. 2017 Jul 25. doi: 10.1111/ane.12797.
    PubMed     Text format     Abstract available


  23. CAMBRON M, Hadhoum N, Duhin E, Lacour A, et al
    JCV serology in time: 3 years of follow-up.
    Acta Neurol Scand. 2017;136:54-58.
    PubMed     Text format     Abstract available


    June 2017
  24. GUAN Z, Shang L, Zhang W, Guo Y, et al
    A rating scale for the severity of Guillain-Barre syndrome.
    Acta Neurol Scand. 2017 Jun 14. doi: 10.1111/ane.12786.
    PubMed     Text format     Abstract available


  25. OTTO M, Markvardsen L, Tankisi H, Jakobsen J, et al
    The electrophysiological response to immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy.
    Acta Neurol Scand. 2017;135:656-662.
    PubMed     Text format     Abstract available


    May 2017
  26. MENTIS AA, Dardiotis E, Grigoriadis N, Petinaki E, et al
    Viruses and endogenous retroviruses in multiple sclerosis: From correlation to causation.
    Acta Neurol Scand. 2017 May 23. doi: 10.1111/ane.12775.
    PubMed     Text format     Abstract available


    April 2017
  27. MARTINELLI V, Dalla Costa G, Messina MJ, Di Maggio G, et al
    Multiple biomarkers improve the prediction of multiple sclerosis in clinically isolated syndromes.
    Acta Neurol Scand. 2017 Apr 9. doi: 10.1111/ane.12761.
    PubMed     Text format     Abstract available


    March 2017
  28. ELKJAER ML, Molnar T, Illes Z
    Teriflunomide for multiple sclerosis in real-world setting.
    Acta Neurol Scand. 2017 Mar 20. doi: 10.1111/ane.12755.
    PubMed     Text format     Abstract available


  29. SCHNEIDER R, Bellenberg B, Kleiter I, Gold R, et al
    Cervical cord and ventricle affection in neuromyelitis optica.
    Acta Neurol Scand. 2017;135:324-331.
    PubMed     Text format     Abstract available


    February 2017
  30. ENSARI I, Pilutti LA, Motl RW
    Depressive symptomology in multiple sclerosis: Disability, cardiorespiratory fitness and heart rate variability.
    Acta Neurol Scand. 2017 Feb 26. doi: 10.1111/ane.12748.
    PubMed     Text format     Abstract available


    January 2017
  31. LUNDELL H, Svolgaard O, Dogonowski AM, Romme Christensen J, et al
    Spinal cord atrophy in anterior-posterior direction reflects impairment in multiple sclerosis.
    Acta Neurol Scand. 2017 Jan 10. doi: 10.1111/ane.12729.
    PubMed     Text format     Abstract available


  32. VOLDSGAARD A, Koch-Henriksen N, Magyari M, Sellebjerg F, et al
    Early safety and efficacy of fingolimod treatment in Denmark.
    Acta Neurol Scand. 2017;135:129-133.
    PubMed     Text format     Abstract available


    December 2016
  33. KARAMYAN A, Brandtner H, Grinzinger S, Chroust V, et al
    Causes of death in critically ill multiple sclerosis patients.
    Acta Neurol Scand. 2016 Dec 23. doi: 10.1111/ane.12724.
    PubMed     Text format     Abstract available


  34. TANASESCU R, Midgley A, Robins RA, Constantinescu CS, et al
    Decreased interferon-beta induced STAT-4 activation in immune cells and clinical outcome in multiple sclerosis.
    Acta Neurol Scand. 2016 Dec 5. doi: 10.1111/ane.12715.
    PubMed     Text format     Abstract available


  35. D'HOOGHE MB, Haentjens P, Van Remoortel A, De Keyser J, et al
    Self-reported levels of education and disability progression in multiple sclerosis.
    Acta Neurol Scand. 2016;134:414-419.
    PubMed     Text format     Abstract available


  36. LITMEIER S, Pruss H, Witsch E, Witsch J, et al
    Initial serum thyroid peroxidase antibodies and long-term outcomes in SREAT.
    Acta Neurol Scand. 2016;134:452-457.
    PubMed     Text format     Abstract available


  37. SIMPSON S JR, Tan H, Otahal P, Taylor B, et al
    Anxiety, depression and fatigue at 5-year review following CNS demyelination.
    Acta Neurol Scand. 2016;134:403-413.
    PubMed     Text format     Abstract available


    November 2016
  38. PEARSON JF, Alla S, Clarke G, Mason DF, et al
    Multiple Sclerosis impact on employment and income in New Zealand.
    Acta Neurol Scand. 2016 Nov 28. doi: 10.1111/ane.12714.
    PubMed     Text format     Abstract available


  39. SOELBERG SORENSEN P
    Safety concerns and risk management of multiple sclerosis therapies.
    Acta Neurol Scand. 2016 Nov 27. doi: 10.1111/ane.12712.
    PubMed     Text format     Abstract available


    October 2016
  40. ZETTL UK, Schreiber H, Bauer-Steinhusen U, Glaser T, et al
    Baseline predictors of persistence to first disease-modifying treatment in multiple sclerosis.
    Acta Neurol Scand. 2016 Oct 30. doi: 10.1111/ane.12705.
    PubMed     Text format     Abstract available


  41. GOUVEIA A, Dias SP, Santos T, Rocha H, et al
    Cognitive impairment and magnetic resonance imaging correlates in primary progressive multiple sclerosis.
    Acta Neurol Scand. 2016 Oct 24. doi: 10.1111/ane.12702.
    PubMed     Text format     Abstract available


  42. ETEMADIFAR M, Mehrabi B, Kiani-Peykani R, Abtahi SH, et al
    Soil heavy metals are associated with the distribution of multiple sclerosis in Isfahan, Iran.
    Acta Neurol Scand. 2016;134:292-9.
    PubMed     Text format     Abstract available


    September 2016
  43. PUZ P, Lasek-Bal A, Radecka P
    Transcranial sonography of subcortical structures in patients with multiple sclerosis.
    Acta Neurol Scand. 2016 Sep 18. doi: 10.1111/ane.12689.
    PubMed     Text format     Abstract available


  44. ROMMER PS, Suhnel A, Konig N, Zettl UK, et al
    Coping with multiple sclerosis-the role of social support.
    Acta Neurol Scand. 2016 Sep 12. doi: 10.1111/ane.12673.
    PubMed     Text format     Abstract available


  45. BRENNER P, Piehl F
    Fatigue and depression in multiple sclerosis: pharmacological and non-pharmacological interventions.
    Acta Neurol Scand. 2016;134 Suppl 200:47-54.
    PubMed     Text format     Abstract available


  46. ROCCA MA, De Meo E, Filippi M
    Functional MRI in investigating cognitive impairment in multiple sclerosis.
    Acta Neurol Scand. 2016;134 Suppl 200:39-46.
    PubMed     Text format     Abstract available


  47. PENNER IK
    Evaluation of cognition and fatigue in multiple sclerosis: daily practice and future directions.
    Acta Neurol Scand. 2016;134 Suppl 200:19-23.
    PubMed     Text format     Abstract available


  48. MUCKSCHEL M, Beste C, Ziemssen T
    Immunomodulatory treatments and cognition in MS.
    Acta Neurol Scand. 2016;134 Suppl 200:55-9.
    PubMed     Text format     Abstract available


  49. BERGER T
    Immunological processes related to cognitive impairment in MS.
    Acta Neurol Scand. 2016;134 Suppl 200:34-8.
    PubMed     Text format     Abstract available


  50. PAUL F
    Pathology and MRI: exploring cognitive impairment in MS.
    Acta Neurol Scand. 2016;134 Suppl 200:24-33.
    PubMed     Text format     Abstract available


  51. PORTACCIO E
    Differential diagnosis, discerning depression from cognition.
    Acta Neurol Scand. 2016;134 Suppl 200:14-8.
    PubMed     Text format     Abstract available


  52. HAMALAINEN P, Rosti-Otajarvi E
    Cognitive impairment in MS: rehabilitation approaches.
    Acta Neurol Scand. 2016;134 Suppl 200:8-13.
    PubMed     Text format     Abstract available


  53. VAN ETTINGER-VEENSTRA H
    Cumulative evidence for MS as a neural network disconnection syndrome consistent with cognitive impairment mechanisms and the confounding role of fatigue and depression-outlook from the Fourth Nordic MS symposium.
    Acta Neurol Scand. 2016;134 Suppl 200:4-7.
    PubMed     Text format     Abstract available


    August 2016
  54. VAGBERG M, Axelsson M, Birgander R, Burman J, et al
    Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society.
    Acta Neurol Scand. 2016 Aug 24. doi: 10.1111/ane.12667.
    PubMed     Text format     Abstract available


  55. CAROTENUTO A, Iodice R, Petracca M, Inglese M, et al
    Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex(R).
    Acta Neurol Scand. 2016 Aug 8. doi: 10.1111/ane.12660.
    PubMed     Text format     Abstract available


    June 2016
  56. RONNING OM, Tornes KD
    Need for symptomatic management in advanced multiple sclerosis.
    Acta Neurol Scand. 2016 Jun 29. doi: 10.1111/ane.12631.
    PubMed     Text format     Abstract available


  57. MOCCIA M, Palladino R, Lanzillo R, Triassi M, et al
    Predictors of the 10-year direct costs for treating multiple sclerosis.
    Acta Neurol Scand. 2016 Jun 29. doi: 10.1111/ane.12630.
    PubMed     Text format     Abstract available


  58. AIVO J, Kurki S, Sumelahti ML, Hanninen K, et al
    Risk of osteoporotic fractures in multiple sclerosis patients in southwest Finland.
    Acta Neurol Scand. 2016 Jun 22. doi: 10.1111/ane.12623.
    PubMed     Text format     Abstract available


  59. ZHOU JY, Xu B, Lopes J, Blamoun J, et al
    Hashimoto encephalopathy: literature review.
    Acta Neurol Scand. 2016 Jun 20. doi: 10.1111/ane.12618.
    PubMed     Text format     Abstract available


  60. SKIERLO S, Rommer PS, Zettl UK
    Symptomatic treatment in multiple sclerosis-interim analysis of a nationwide registry.
    Acta Neurol Scand. 2016 Jun 9. doi: 10.1111/ane.12612.
    PubMed     Text format     Abstract available


    May 2016
  61. SIMONSEN CS, Edland A, Berg-Hansen P, Celius EG, et al
    High prevalence and increasing incidence of multiple sclerosis in the Norwegian county of Buskerud.
    Acta Neurol Scand. 2016 May 30. doi: 10.1111/ane.12615.
    PubMed     Text format     Abstract available


  62. KOLASA M, Hagman S, Verkkoniemi-Ahola A, Airas L, et al
    Anti-JC virus seroprevalence in a Finnish MS cohort.
    Acta Neurol Scand. 2016;133:391-7.
    PubMed     Text format     Abstract available


    April 2016
  63. PRESS R, Hiew FL, Rajabally YA
    Steroids for chronic inflammatory demyelinating polyradiculoneuropathy: evidence base and clinical practice.
    Acta Neurol Scand. 2016;133:228-38.
    PubMed     Text format     Abstract available


  64. HOLMOY T, Esbensen QY, Torkildsen O, Wergeland S, et al
    WT1 and interferon-beta-vitamin D association in MS: a longitudinal study.
    Acta Neurol Scand. 2016;133:309-12.
    PubMed     Text format     Abstract available


    March 2016
  65. VON RHEIN B, Wagner J, Widman G, Malter MP, et al
    Suspected antibody negative autoimmune limbic encephalitis: outcome of immunotherapy.
    Acta Neurol Scand. 2016 Mar 4. doi: 10.1111/ane.12575.
    PubMed     Text format     Abstract available


    February 2016
  66. SANTANGELO G, Sacco R, Siciliano M, Bisecco A, et al
    Anxiety in Multiple Sclerosis: psychometric properties of the State-Trait Anxiety Inventory.
    Acta Neurol Scand. 2016 Feb 1. doi: 10.1111/ane.12564.
    PubMed     Text format     Abstract available


    January 2016
  67. MILLER E, Kostka J, Wlodarczyk T, Dugue B, et al
    Whole-body cryostimulation (cryotherapy) provides benefits for fatigue and functional status in multiple sclerosis patients. A case-control study.
    Acta Neurol Scand. 2016 Jan 18. doi: 10.1111/ane.12557.
    PubMed     Text format     Abstract available


    January 2015
  68. ANDERSEN O
    Conclusion: National incidence and risk factor assessments may become a basis for the evaluation of prevention trials - prospects from the Third Nordic MS Symposium.
    Acta Neurol Scand. 2015;132:71-5.
    PubMed     Text format     Abstract available


  69. AIRAS L
    Hormonal and gender-related immune changes in multiple sclerosis.
    Acta Neurol Scand. 2015;132:62-70.
    PubMed     Text format     Abstract available


  70. SUNDSTROM P, Salzer J
    Vitamin D and multiple sclerosis-from epidemiology to prevention.
    Acta Neurol Scand. 2015;132:56-61.
    PubMed     Text format     Abstract available


  71. CORREALE J, Gaitan MI
    Multiple sclerosis and environmental factors: the role of vitamin D, parasites, and Epstein-Barr virus infection.
    Acta Neurol Scand. 2015;132:46-55.
    PubMed     Text format     Abstract available


  72. BOSTROM I, Landtblom AM
    Does the changing sex ratio of multiple sclerosis give opportunities for intervention?
    Acta Neurol Scand. 2015;132:42-5.
    PubMed     Text format     Abstract available


  73. BERG-HANSEN P, Celius EG
    Socio-economic factors and immigrant population studies of multiple sclerosis.
    Acta Neurol Scand. 2015;132:37-41.
    PubMed     Text format     Abstract available


  74. GRYTTEN N, Torkildsen O, Myhr KM
    Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades.
    Acta Neurol Scand. 2015;132:29-36.
    PubMed     Text format     Abstract available


  75. MYHR KM, Grytten N, Torkildsen O, Wergeland S, et al
    The Norwegian Multiple Sclerosis Registry and Biobank.
    Acta Neurol Scand. 2015;132:24-8.
    PubMed     Text format     Abstract available


  76. MAGYARI M
    Role of socio-economic and reproductive factors in the risk of multiple sclerosis.
    Acta Neurol Scand. 2015;132:20-3.
    PubMed     Text format     Abstract available


  77. HILLERT J, Stawiarz L
    The Swedish MS registry - clinical support tool and scientific resource.
    Acta Neurol Scand. 2015;132:11-9.
    PubMed     Text format     Abstract available


  78. KOCH-HENRIKSEN N, Magyari M, Laursen B
    Registers of multiple sclerosis in Denmark.
    Acta Neurol Scand. 2015;132:4-10.
    PubMed     Text format     Abstract available


  79. ANDERSEN O
    Nordic MS Epidemiology. Introduction.
    Acta Neurol Scand. 2015;132:1-3.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: